Sign In
Buy IBRX
$7.18
-0.0500 (-0.692%)
At Close: Jun 03, 2026
IBRX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
10:14am, Tuesday, 21'st Apr 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their Options If you purchased or acqu
ImmunityBio Stock Rises As ANKTIVA Launches in Saudi Arabia
09:44am, Tuesday, 21'st Apr 2026
ImmunityBio, Inc. (NASDAQ:IBRX) shares are trading higher Tuesday after the company announced that ANKTIVA is now available in Saudi Arabia for bladder and lung cancer patients.
NEW YORK, April 21, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc. (NASDAQ: IBRX). Shareholders who purchased shares of IBRX during the class
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or a
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that ANKTIVA® (nogapendekin alfa inbakicept) is now commercially avai
New York, New York--(Newsfile Corp. - April 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ:
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP encourages investors who suffered losses in ImmunityBio, Inc. (NASDAQ: IBRX) to contact the firm. WHO IS AFFECTED: Those who purchase
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
01:33pm, Monday, 20'th Apr 2026
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. , a top complex litigation law firm, is investigating ImmunityBio Inc. (NASDAQ: IBRX) (“ImmunityBio” or the “Company”) for po
Kessler Topaz Meltzer & Check, LLP - ImmunityBio, Inc. Class Action Lawsuit: Investors Face May 26, 2026, Deadline
01:06pm, Monday, 20'th Apr 2026
Did you buy IBRX securities between January 19, 2026, and March 24, 2026? Affected IBRX Investor Summary Who: ImmunityBio, Inc. (NASDAQ: IBRX) What: Securities fraud class action lawsuit filed Class
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ImmunityBio To Contact Him Directly To Discuss Their Options If you purchased or acqu
SAN FRANCISCO, April 20, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired Immuni
San Diego, California--(Newsfile Corp. - April 20, 2026) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities betwee
ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IBRX
03:09am, Monday, 20'th Apr 2026
LOS ANGELES, April 20, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of §
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Sunday, 19'th Apr 2026
New class action for ImmunityBio (IBRX) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 5/26/2026
